Savara Inc. (NASDAQ:SVRA - Get Free Report)'s share price rose 8% on Thursday . The stock traded as high as $2.95 and last traded at $2.92. Approximately 1,517,254 shares traded hands during mid-day trading, an increase of 25% from the average daily volume of 1,212,930 shares. The stock had previously closed at $2.70.
Analyst Upgrades and Downgrades
SVRA has been the topic of several research analyst reports. Evercore ISI decreased their price target on shares of Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a report on Wednesday, May 28th. Guggenheim reaffirmed a "buy" rating and issued a $8.00 price target (down previously from $9.00) on shares of Savara in a report on Wednesday, May 28th. Wells Fargo & Company decreased their price target on shares of Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Wednesday, May 28th. Finally, HC Wainwright cut shares of Savara from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $6.00 to $2.00 in a report on Thursday, May 29th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Savara presently has an average rating of "Moderate Buy" and an average target price of $5.60.
Get Our Latest Stock Report on Savara
Savara Trading Up 13.1%
The firm has a market cap of $528.03 million, a P/E ratio of -6.24 and a beta of 0.40. The company has a debt-to-equity ratio of 0.20, a current ratio of 14.91 and a quick ratio of 14.91. The stock has a 50 day moving average of $2.37 and a 200 day moving average of $2.66.
Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.02). As a group, equities research analysts predict that Savara Inc. will post -0.45 EPS for the current year.
Insider Activity
In other Savara news, Director Richard J. Hawkins bought 48,225 shares of the business's stock in a transaction that occurred on Friday, June 20th. The shares were bought at an average cost of $2.04 per share, with a total value of $98,379.00. Following the completion of the purchase, the director directly owned 115,466 shares of the company's stock, valued at $235,550.64. This trade represents a 71.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 5.33% of the stock is owned by insiders.
Institutional Trading of Savara
Large investors have recently modified their holdings of the business. XTX Topco Ltd bought a new stake in shares of Savara in the fourth quarter worth about $34,000. Ameriprise Financial Inc. bought a new stake in shares of Savara in the fourth quarter worth about $37,000. Prudential Financial Inc. bought a new stake in shares of Savara in the second quarter worth about $30,000. May Hill Capital LLC bought a new stake in shares of Savara in the second quarter worth about $32,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Savara in the fourth quarter worth about $48,000. 87.93% of the stock is owned by institutional investors.
Savara Company Profile
(
Get Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.